Low vitamin D is associated with poorer prognosis, thicker tumours, ulceration and increased inflammation in primary melanoma¹ . Testing is recommended by the National Institute of Clinical Excellence (NICE) in the UK for any new patient diagnosed with melanoma but not for those with already established or metastatic disease. Driver mutations in BRAF are found in approximately 50% of melanomas and play an important role in cell proliferation, metastases and increases inflammation by promoting secretion of pro-inflammatory cytokines including Interleukin (IL) 6 and IL 8² . This article is protected by copyright. All rights reserved.